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Differential Hox Expression in Murine Embryonic Stem
Cell Models of Normal and Malignant Hematopoiesis
Helen Wheadon,1,* Joanne M. Ramsey,2,* Edwina Dobbin,1 Glenda J. Dickson,2
Pamela M. Corrigan,3 Robin W. Freeburn,4 and Alexander Thompson2
The Hox family are master transcriptional regulators of developmental processes, including hematopoiesis. The
Hox regulators, caudal homeobox factors (Cdx1-4), and Meis1, along with several individual Hox proteins, are
implicated in stem cell expansion during embryonic development, with gene dosage playing a significant role in
the overall function of the integrated Hox network. To investigate the role of this network in normal and
aberrant, early hematopoiesis, we employed an in vitro embryonic stem cell differentiation system, which
recapitulates mouse developmental hematopoiesis. Expression profiles of Hox, Pbx1, and Meis1 genes were
quantified at distinct stages during the hematopoietic differentiation process and compared with the effects of
expressing the leukemic oncogene Tel=PDGFRb. During normal differentiation the Hoxa cluster, Pbx1 and Meis1
predominated, with a marked reduction in the majority of Hox genes (27=39) and Meis1 occurring during
hematopoietic commitment. Only the posterior Hoxa cluster genes (a9, a10, a11, and a13) maintained or increased
expression at the hematopoietic colony stage. Cdx4, Meis1, and a subset of Hox genes, including a7 and a9,
were differentially expressed after short-term oncogenic (Tel=PDGFRb) induction. Whereas Hoxa4-10, b1, b2, b4,
and b9 were upregulated during oncogenic driven myelomonocytic differentiation. Heterodimers between
Hoxa7=Hoxa9, Meis1, and Pbx have previously been implicated in regulating target genes involved in
hematopoietic stem cell (HSC) expansion and leukemic progression. These results provide direct evidence that
transcriptional flux through the Hox network occurs at very early stages during hematopoietic differentiation and
validates embryonic stem cell models for gaining insights into the genetic regulation of normal and malignant
hematopoiesis.
Introduction
Embryonic stem (ES) cells have become an establishedmodel to investigate early hematopoiesis in an in vitro
setting [1,2]. Murine ES cells can be induced to differentiate by
removal of the growth factor leukemia inhibitory factor (LIF)
from the media. Differentiation induction leads to the pro-
duction of defined colonies termed embryoid bodies (EBs)
that contain developing cell populations of all 3 germ layers
[1–3]. Mesoderm-derived cells within the EBs can subse-
quently be stimulated to produce blast-like colonies (BC) that
under specific conditions can differentiate further giving rise
to myeloid, erythroid, and lymphoid cells that constitute the
hematopoietic lineages. Several studies have previously
validated this model on the basis of gene expression and
progenitor cell assays [1,2,4]. In a previous study, we carried
out comparative analysis of the Wnt signaling pathway,
which is a major regulator of hematopoiesis, using an ES
model of differentiation and primary tissues and showed
substantial overlap in expression that was both stage and
organ specific [5]. This previous work emphasizes the ap-
propriateness of the ES model as a tool to study transcrip-
tional flux through genetic networks during hematopoietic
differentiation.
The HOX network is comprised of the clustered class I
homeobox genes, which encode master regulators of devel-
opment. The mammalian 39 Hox genes are evolutionarily
highly conserved and appear to have arisen by a process of
duplication and divergence from a primordial gene (re-
viewed by Duboule [6]). Mammalian Hox genes are located
as up to 13 paralogs within 4 clusters (A, B, C, and D) on
separate chromosomes (7, 17, 12, and 2, in human; 6, 11, 15,
and 2, in mouse). During embryonic development Hox genes
are expressed sequentially (30–50) along the anterior-posterior
axis, with 30 genes such as Hoxa1 expressed earlier and more
anteriorly than 50 genes, such as Hoxa13 [7,8]. Deregulated
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Hox expression at the individual gene level tends to result in
subtle phenotypic changes, most likely due to a high level of
redundancy built into the network.
Hox expression during definitive hematopoiesis has been
relatively well studied in both mouse and human with the
majority of the Hox genes being expressed predominantly in
the hematopoietic stem=progenitor cell (HSPC) compart-
ment. Hox gene expression appears linked to and may
specify in part hematopoietic lineage and stage of differen-
tiation. In particular, the A and B clusters, which are pref-
erentially expressed in the most primitive hematopoietic
cells, exhibit reduced expression after lineage commitment
(reviewed by Argiropoulos and Humphries [9]). Such ob-
servations led to the hypothesis that self-renewal of HSPCs is
Hox dependent and that inappropriate Hox expression ob-
served in myeloid leukemias underlies maintenance of the
leukemia-initiating cell [10,11]. The role of Hox genes in he-
matopoiesis has also been studied using gene-targeting
strategies. Both gain-of-function and loss-of-function mu-
tants have provided insight into the role of individual Hox
genes in hematopoiesis. Ectopic expression of Hoxa9 results
in increased HSPC self-renewal that results in acute leukemia
with a long latency [12,13], whereas overexpression of Hoxb4
results in stem cell expansion in the absence of overt leuke-
mia [14–16]. Similarly, Hoxa9-deficient mice display a dra-
matic phenotype consistent with reduced HSPC self-renewal
[17,18], whereas Hoxb4-deficient mice are normal [19]. The
difference in phenotype between these 2 models may be re-
lated to the significantly higher expression of Hoxa9 than that
of Hoxb4 in normal HSPCs [18].
Several studies have implicated aberrant regulation of the
Cdx family and the Hoxa and Hoxb clusters in myeloid ma-
lignancies especially acute myeloid leukemia (AML) [20,21].
However, a role for Hox genes in myeloproliferative neo-
plasms (MPN) has not been clearly defined. The
t(5:12)(q33;p13) translocation, identified in a subset of pa-
tients with the MPN chronic myelomonocytic leukemia, fu-
ses an Ets-related transcription factor (Tel) to the PDGFRb
gene, producing the Tel=PDGFRb (TP) tyrosine kinase-active
fusion protein [22]. Previous studies using tetracycline (Tet)-
regulated expression of TP recapitulated observed findings
for TPþ patient samples, in particular alterations in the he-
matopoietic transcriptional network that drives myelomo-
nocytic differentiation [23,24]. In this study, we have
employed a previously established hematopoietic differen-
tiation model [5] to determine the Hox transcriptional profile
during primitive and more definitive hematopoietic com-
mitment. The effects of the leukemic oncogene on this gene
signature were then examined to determine how perturbed
myelopoiesis alters the Hox network. Cells were collected at
key stages during hematopoietic differentiation along the
mesodermal-hemangioblast-hematopoietic axis for quantita-
tive expression profiling. Our results clearly demonstrate
transcriptional flux through the Hox network and regulation
of specific Hox subsets during hematopoietic differentiation
of ES cells, with specific changes observed in our leukemic
model. These findings are consistent with a combination of
global regulation of Hox clusters and targeted regulation of
individual Hox genes (or subsets) during hematopoietic
commitment. This study highlights that transcriptional
fluxes in the Hox network play a role in deregulation of
myelopoiesis in MPN.
Materials and Methods
Hematopoietic differentiation of ES cells
and ES-TP clones
Hematopoietic differentiation was performed as previ-
ously described [5]. Primary EBs were generated from single-
cell suspensions of ES parental cells or ES-TP clones in the
presence or absence of 500mg=mL Tet. Cell were plated at
1104=mL in low adhesion Petri dishes in the following
basal media: 1% methylcellulose (Sigma-Aldrich Technolo-
gies), 1 Iscove’s modified Dulbecco’s medium (IMDM)
(Invitrogen Life Technologies), 100 mg=mL holo-transferrin,
10 mg=mL insulin, 104 M 2-Mercaptoethanol, 50mg=mL
ascorbic acid (Sigma-Aldrich Technologies), 15% fetal calf
serum (FCS; Invitrogen Life Technologies) supplemented
with the following growth factors to promote good meso-
dermal differentiation, 10 ng=mL bone morphogenetic pro-
tein-4 (BMP-4; R&D Systems Ltd., Abingdon), 2 ng=mL
Activin A, and 10 ng=mL basic fibroblast growth factor
(bFGF; PeproTech). After 3.75 days in culture EBs were
harvested, washed3 with phosphate-buffered saline (PBS),
and treated with 0.25% trypsin–ethylenediaminetetraacetic
acid for 3min. Cells were replated at 1105=mL in basal
media supplemented with the following growth factors to
promote hemangioblast formation: 100 ng=mL stem cell fac-
tor (SCF), 10 ng=mL interleukin-6 (IL-6), and 10 ng=mL vas-
cular endothelial growth factor (VEGF; PeproTech). After 4
days of culture, EBs and BCs were harvested as outlined and
a single-cell suspension replated at 2.5104=mL in basal
media supplemented with 1% bovine serum albumin (In-
vitrogen Life Technologies) and cytokines to promote both
myeloid and erythroid colony formation: 25 ng=mL GM-CSF,
25 ng=mL G-CSF, 10 ng=mL SCF, 10 ng=mL IL-3 (Pepro-
Tech), and 2U=mL erythropoietin (EPO) (R&D Systems Ltd).
After further culture for 7 days, hematopoietic colonies
(HCs) were scored using a Nikon Eclipse TS100 microscope
and digital camera imaging system.
Cell culture
CCE and E14tg2a (expressing the Tet-sensitive transacti-
vator) murine ES cells [25] were routinely cultured on tissue
culture plates (Nunc) coated with 0.1% (v=v) porcine gelatin
(Sigma-Aldrich Technologies) as described previously [23].
The ES-TP clones were cultured as previously described [24].
For induction of expression of TP clones were washed 3
with PBS and incubated in LIF-containing media in the
presence of 500 ng=mL Tet to prevent expression of TP, or no
Tet to induce the expression of TP.
Conditional expression of TP
TP clones (TP1 and TP14) were plated at 1105–1106
cells per gelatin-coated 100mm tissue culture dish. Cells
were cultured with and without Tet for 24, 48, or 72 h to
induce the short-term expression of TP. After treatment, the
cells were harvested and washed3 with ice-cold PBS before
being lysed as described previously [24]. Protein concentra-
tions were determined using a Bio-Rad protein assay kit.
Delayed TP activation was initiated by removal of Tet at the
BC stage (day 4 culture—LIF) or the HC stage (day 8—LIF)
of development. BC cells with delayed TP activation cells
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were collected at day 8—LIF (day 4 TPþ) and the corre-
sponding HC cells at day 15—LIF (day 7 TPþ). Delayed TP-
activated cells were examined by colony assays and total
RNA isolated for polymerase chain reaction (PCR) and real
time quantitative (RQ)-PCR analyses.
Immunoblotting and antibodies
For immunoblotting, 20mg of each cell lysate was frac-
tionated by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis and blotted onto nitrocellulose. Primary
antibodies were used at the following dilutions: 0.1mg=mL
anti-phosphotyrosine 4G10 (05–32; Upstate Biotechnology);
0.5mg=mL PDGFRb antibody, which recognizes TP (CST 3162;
New England Biolabs); and 1:2,000 anti-SHP-2 (sc-293; Santa
Cruz Biotechnology Inc.). Secondary antibodies conjugated to
horseradish peroxidase (Dako) were used at 1:10,000 dilution
and blots developed using ECL (Amersham Pharmacia).
FDCP-Mix cells
Factor dependent cell Paterson (FDCP)-Mix cells stably
expressing the TP oncogene or empty vector (EV) were
maintained in Fishers medium with 20% (v=v) horse serum
supplemented with 10 ng=mL IL-3 (R&D Systems). For dif-
ferentiation induction, FDCP-Mix cells were washed 3 times
in PBS and cultured in IMDM with 20% fetal bovine serum
(Invitrogen Life Technologies) and cytokines to induce
monocytic and neutrophilic commitment (0.1 ng=mL IL-3,
10 ng=mL GM-CSF, 5 ng=mL M-CSF, and 10 ng=mL G-CSF;
PeproTech).
Flow cytometry
During hematopoietic differentiation, cells were harvested
at the primary EB, and secondary EB=BC colony for ES cell, or
at days 0, 4, and 7 of differentiation for the FDCP-mix cells
and analyzed by fluorescence-activated cell sorting (FACS).
EBs were treated with trypsin for 2min, neutralized with FCS,
washed3 with PBS, and resuspended at 0.5105 cells=100mL
of FACS Buffer (PBS with 2% FCS and 0.02% sodium azide).
Cells were blocked with 1mg of Purified Rat Anti-Mouse
CD16=CD32 Fc Block (Becton Dickinson, BD 553142) for 1 h
at 48C. Labeling was performed using 0.5mg of each flur-
ochrome-conjugated antibody or relevant isotype control for
1 h at 48C in the dark. Secondary staining was performed for a
further 30min for any indirect stains: Flk-1 (VEGF-R2, Ly-73;
BD 555308), Brachyury (Abcam 20680), Sca 1 (BD 558162), c-
Kit (CD 117; BD 553356), CD 11b (BD 552850), Gr1 (BD
553129), FITC Secondary (BD 554020), Step-Avidin Secondary
(BD 554064). Cells were washed in 2mL of FACS Buffer,
pelleted 1,200 rpm for 5min at 48C. Cells were resuspended in
300mL of FACS Buffer and analyzed on a FACSCanto II
flow cytometer (BD) and data analyzed using FlowJo software.
PCR analyses
Total RNA was prepared using RNAeasy Plus extraction
kit (Qiagen). RNA (1mg) was reverse-transcribed using Su-
perscript reverse transcriptase and oligo dT primers (In-
vitrogen Life Technologies). PCR was performed using 2mL
of cDNA and standard conditions with gene-specific primers
as previously reported [5].
Real-time quantitative PCR
RQ-PCR was performed as previously reported [26].
Briefly, total RNA was extracted from cells using RNAesay
Plus extraction kit, cDNA was prepared, and RQ-PCR was
achieved using TaqMan probe-based chemistry (Applera)
and the ABI PRISM 7500 system (Perkin Elmer-Applied
Biosystems). The murine Hox-specific oligonucleotide sets
were designed using Primer Express (Applera) and vali-
dated by standard PCR cloning and DNA sequencing of at
least 5 colonies. Hox target copy numbers (copies per 50 ng
RNA equivalents) were obtained from plasmid-derived
standard curves [27]. The 18S rRNA predeveloped assay
reagent (Applera) was used as endogenous control. RQ-PCR
data are reported as either cycle threshold (CT) values cor-
rected to endogenous control, which refers to the accumu-
lation of sufficient PCR product to transect a user-defined
threshold (lower CT values indicate higher gene expression)
or as fold change, which was calculated using the 2DDCT
method and assumes doubling of the amount of product
with each PCR cycle.
Statistical analysis
Data generated from biological and technical replicates
were analyzed by the Paired, 2-tailed Student’s t-test: þP<
0.05 and *P< 0.001.
Results
Hematopoietic differentiation of ES cells
Differentiation of the E14tg2a and CCE ES cell lines was
performed using a modified protocol based on the original
work of Keller and colleagues [1]. The directed differentiation
was validated by morphological analysis that confirmed ap-
propriate formation of 18 EBs, BCs, and HCs at key stages of
hematopoietic development. Hemoglobinized erythroid cells
were observed within the BCs and distinct CFU-GM, BFU-E,
and GEMM colonies were identified by day 15 of culture
(Fig. 1A) consistent with these established models [1,5]. The
differentiation model was validated and characterized based
on expression of known ES self-renewal and differentiation
genes. Expression of self-renewal markers such as Oct-4 and
Nanog decreased during differentiation in congruence with
upregulation of maturation and lineage-specific markers such
as FGF5, FIK-1, Hbb-b1, PU1, and MafB (Fig. 1B and as pre-
viously reported [5]). Maturation through the key stages of
development was also associated with altered levels of
brachyury, Flk-1, c-Kit, and Sca-1 (Supplementary Fig. S1;
Supplementary Data are available online at www.liebertonline
.com=scd) and differential expression of the Hox-regulator
caudal homeobox-4 (Cdx4) gene and Hoxb4 (Fig. 1C).
Complete Hox network profiling during hematopoietic
differentiation of ES cells
Undifferentiated murine ES cells displayed a wide range
of expression of Hox elements with corrected CT values be-
tween 34 and 19, corresponding to 20 and 3105 copies for
Hoxd9 and Hoxa1, respectively. All Hox genes were expressed
to a measurable amount (CT< 36) in both murine ES cell
lines (Fig. 2 and data not shown). The vast majority of the
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Hox genes (27=39) displayed reduced expression after in-
duction of the differentiation program, and this reduction
was either transient (12=27) or sustained (15=27) for the du-
ration of the differentiation process (Fig. 2 and Supplemen-
tary Fig. S2a–d). Of the 8 genes that showed measurable
(DCT 2) upregulation upon EB formation, only 1 was from
the Hoxa cluster (a13), 2 from the Hoxc cluster (c8 and c10),
and 5 from the Hoxd cluster (d1, d3, d4, d9, and d10). Tran-
sition from the EB to the BC development stage resulted in
measurable upregulation in 20=41 genes analyzed, including
the 3-amino loop extension (TALE) genes Pbx1 and Meis1 as
well as downregulation in Hoxb1 and c13. Further differen-
tiation to the HC stage resulted in global upregulation of the
Hoxc cluster and general downregulation in the other genes
with the notable exception of Hoxa13, b13, and Meis1 (Sup-
plementary Fig. S2a–d). Due to their preponderance in he-
matopoiesis, further comparative analysis of Hoxa expression
was performed during hematopoietic differentiation of both
E14tg2a and CCE cell lines. Two distinct patterns of ex-
pression emerged whereby the 30 genes (Hoxa1-Hoxa7) were
downregulated during hematopoietic differentiation and the
50 genes (Hoxa9-Hoxa13) tended to be upregulated during
this process (Fig. 3). These data suggest coordinated ex-
pression of Hox genes in ES cells.
Conditional expression of TP in an ES model
of leukemia
Previous studies investigating the role of TP during he-
matopoietic differentiation of ES cells indicated that this
FIG. 1. In vitro hematopoietic differentiation of murine embryonic stem (ES) cells. (A) Schematic diagram of the 3 stages
involved in hematopoietic differentiation of ES cells and the growth factor combinations used. Photographs of representative
primary embryoid bodies (EB), blast colonies (BC), and hematopoietic colonies (HCs) taken at 10magnification. Table of the
percentage of morphologically identified colonies within the HC by day 15. (B) Reverse transcription-polymerase chain reaction
(RT-PCR) analysis at key ES cell differentiation stages. Expression of known self-renewal and corresponding lineage-specific
markers were examined, with the housekeeping gene GusB as control. (C) RT-PCR analysis of Hoxb4 and Cdx4 expression
obtained from cells at the key stages of development. The low expression housekeeping genes (TBP and GusB) were included as
positive controls.
1468 WHEADON ET AL.
oncogene can upregulate several transcription factors in-
volved in regulating HSC expansion, including Hoxb4 and
Cdx4 [24]. Several studies have shown that the Cdx family are
global regulators ofHox gene expression. Removal of Tet from
cultured ES-TP clones induced robust expression of TP that
was maintained for up to 72h (Fig. 4A). Immunoblotting
analysis showed comparable levels of TP protein in 2 in-
dependent clones that resulted in functional signal trans-
duction from the oncogenic receptor as detected by the
anti-phosphotyrosine antibody. Induced TP expression (up to
72h) resulted in increased expression of Hoxb4 and Cdx4 (Fig.
4B and ref. [24]) and decreased ES cell self-renewal and pro-
liferation as verified by reduced alkaline phosphatase staining
(Fig. 4C). This resulted in altered morphology consistent with
a more differentiated phenotype as previously described [24].
Complete Hox network profiling after short-term
TP expression in ES cells
RQ-PCR profiling of the Hox network in ES-TP cells
showed measurable expression (CT <36) of all genes except
Hoxd3. As was the case in the parental line a wide range of
Hox expression was observed with CT values ranging be-
tween 35 and 24, corresponding to between 10 and 2104
copies for Hoxb1 and Hoxa3, respectively. Short-term induc-
tion of TP (24 h) resulted in moderate to substantial alteration
in Hox expression as depicted by changes in corrected CT
values (Supplementary Table S1). A subset of genes from the
Hoxa and b clusters (n¼ 13) plus the cofactor genes Pbx1 and
Meis1 were identified as candidates for further time-course
study.
xoHxoH
a1 19.3  ± 0.3 21.7  ± 0.0 20.7  ± 0.1 21.3  ± 0.1 c4 26.0  ± 0.1 30.4  ± 0.2 27.3  ± 0.4 25.1  ± 0.2
a2 21.3  ± 0.1 23.4  ± 0.0 23.9  ± 0.2 24.4  ± 0.0 c5 25.5  ± 0.2 28.6  ± 0.1 27.5  ± 0.1 26.7  ± 0.3 18-21
a3 19.6  ± 0.2 22.4  ± 0.2 23.0  ± 0.4 23.2  ± 0.2 c6 22.1  ± 0.2 24.6  ± 0.1 22.6  ± 0.2 20.1  ± 0.2 21-24
a4 20.1  ± 0.1 23.9  ± 0.0 23.4  ± 0.0 22.4  ± 0.2 c8 29.0  ± 0.1 24.5  ± 0.2 22.5  ± 0.1 21.2  ± 0.1 24-27
a5 20.0  ± 0.1 23.4  ± 0.2 22.4  ± 0.2 23.8  ± 0.3 c9 22.9  ± 0.1 26.4  ± 0.2 23.3  ± 0.0 21.4  ± 0.2 27-30
a6 19.7  ± 0.2 19.3  ± 0.1 18.0  ± 0.1 19.2  ± 0.2 c10 28.6  ± 0.2 24.7  ± 0.1 20.5  ± 0.1 19.5  ± 0.2 30-35
a7 20.5  ± 0.1 22.5  ± 0.0 21.1  ± 0.0 20.6  ± 0.1 c11 22.9  ± 0.0 26.8  ± 0.2 24.9  ± 0.2 22.3  ± 0.1
a9 22.1  ± 0.2 25.7  ± 0.3 24.4  ± 0.2 24.7  ± 0.1 c12 22.6  ± 0.2 26.8  ± 0.1 26.4  ± 0.1 23.9  ± 0.1
a10 22.1  ± 0.2 26.9  ± 0.1 26.7  ± 0.4 25.3  ± 0.1 c13 22.2  ± 0.1 25.9  ± 0.1 28.3  ± 0.2 26.9  ± 0.2
a11 21.0  ± 0.2 24.2  ± 0.3 20.2  ± 0.2 18.9  ± 0.1 d1 30.0  ± 0.1 26.4  ± 0.2 26.2  ± 0.2 26.8  ± 0.1
a13 27.5  ± 0.1 25.1  ± 0.4 20.2  ± 0.2 19.7  ± 0.1 d3 30.8  ± 0.0 27.1  ± 0.1 24.4  ± 0.2 25.2  ± 0.0
b1 21.4  ± 0.1 21.9  ± 0.1 24.1  ± 0.3 26.8  ± 0.1 d4 32.1  ± 0.2 28.2  ± 0.4 25.4  ± 0.0 26.6  ± 0.2
b2 22.6  ± 0.1 24.0  ± 0.1 22.9  ± 0.2 25.1  ± 0.1 d8 26.0  ± 0.0 27.6  ± 0.3 25.7  ± 0.0 24.8  ± 0.2
b3 21.6  ± 0.2 24.6  ± 0.2 23.4  ± 0.8 26.2  ± 0.2 d9 34.0  ± 0.1 29.7  ± 0.1 28.4  ± 0.1 27.9  ± 0.2
b4 22.4  ± 0.1 25.9  ± 0.5 23.2  ± 0.2 24.7  ± 0.1 d10 32.1  ± 0.1 26.2  ± 0.1 23.1  ± 0.2 23.9  ± 0.0
b5 24.8  ± 0.2 24.8  ± 0.0 20.7  ± 0.1 24.3  ± 0.0 d11 22.8  ± 0.2 23.4  ± 0.2 19.7  ± 0.1 19.8  ± 0.2
b6 22.3  ± 0.2 25.7  ± 0.0 24.2  ± 0.1 26.2  ± 0.2 d12 23.1  ± 0.2 27.4  ± 0.1 23.7  ± 0.1 26.0  ± 0.1
b7 20.1  ± 0.1 23.0  ± 0.0 19.4  ± 0.2 20.4  ± 0.2 d13 25.4  ± 0.3 26.1  ± 0.1 21.8  ± 0.2 22.4  ± 0.1
b8 22.3  ± 0.1 25.8  ± 0.2 23.1  ± 0.1 25.7  ± 0.0 Pbx1 20.0  ± 0.1 21.0  ± 0.1 18.6  ± 0.1 19.1  ± 0.0
b9 21.3  ± 0.1 24.8  ± 0.1 22.8  ± 0.2 25.6  ± 0.3 Meis1 21.7  ± 0.2 26.2  ± 0.2 21.0  ± 0.3 19.8  ± 0.2
b13 20.4  ± 0.3 24.7  ± 0.1 23.6  ± 0.2 21.1  ± 0.1
control 1° EB BC HC control 1° EB BC HC
Key FIG. 2. Array of Hox-Tale
gene profiles in differentiat-
ing murine embryonic stem
cells. Real-time quantitative
PCR (RQ-PCR) expression
analysis of Hox and cofactor
genes at key development
stages (1) undifferentiated
(control), (2) primary EB (18
EB), (3) BC, and (4) HC for-
mation. Representative mean
cycle threshold (CT) values
obtained from triplicate ex-
periments normalized to 18S
rRNA standard error (SE)
are tabulated. Lowest CT
values (18–20) reflect highest
expression; highest CT values
(32–35) reflect lowest expres-
sion.
FIG. 3. Reciprocal coordinated ex-
pression of the Hoxa cluster in dif-
ferentiating murine embryonic stem
(ES) cells. Representative histogram
plots of copy number (per 50 ng of
RNA) in expression of the Hoxa
cluster in 2 independent cell lines
(CCE and E14tg2a) from primary EB
(18 EB): BC and HC formation com-
pared with undifferentiated control
cells. Values were obtained from
triplicate experiments and normal-
ized to 18S rRNA SE. {P< 0.05 and
*P< 0.001.
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Candidate Hox gene expression during sustained
TP activation in ES and FDCP-Mix cells
Hox genes that demonstrated differential expression after
short-term TP activation (24h)were further analyzed in a time-
course study over 3 days that correlates with substantial
differentiation of TP expressing cells (Fig. 4 and [24]). The
candidate genes were all expressed at measurable levels (CT
<36) throughout the time course. Significant changes in ex-
pression (P< 0.05) were observed throughout the time course
(Fig. 5). The majority of the candidate genes demonstrated an
initial reduction in expression after TP induction (9=15) that
was either transient (7=9) or sustained (2=9) over the 3 days.
Hoxa6was the most predominantly expressed of the candidate
genes and was significantly upregulated at the 72h time point.
Hoxa10 exhibited sustained repression (4-fold) after TP acti-
vation. Five genes,Hoxa13, b2, b4, b5, andMeis1, demonstrated
initial upregulation in expression after TP induction that was
sustained or steadily increased (up to 16-fold forMeis1) during
the time course, as the TP expressing cells differentiate (Fig. 5).
Of most interest was upregulation of Hoxa6, a7, a9, b2, b3, b4,
Pbx1, and Meis1 in the TP-induced differentiated cells. These
genes have previously been linked to hematopoietic regulation
and deregulation of myelopoiesis in leukemia.
Ectopic expression of TP in the multipotent FDCP-Mix
murine cell line resulted in pTyr activation and modified
differentiation as defined by increased Sca-1 and decreased
CD 11b and Gr-1 expression compared with control cells
(Supplementary Fig. S3). Although baseline Hox expression
was an order of magnitude lower in this model compared
with the ES cells, increased expression in the constitutively
active TP cells (day 0) was observed for Hoxa6, a7, a9, a10, b2,
b3, b4, b9, and Meis1 (Supplementary Fig. S4). Extended
differentiation of the FDCP-Mix cells, up to day 7, resulted in
significantly reduced levels of Hox as expected. Meis1 ex-
pression was consistently higher than the Hox genes in the
differentiating FDCP-Mix cell lines, and TP activation re-
sulted in maintained increased expression of Meis1 com-
pared with EV controls.
TP modulates key Hox genes during hematopoietic
differentiation of ES cells
To examine transcriptional flux through the Hox network
in a leukemia-differentiation model, inducible TP-ES cells
were directed to undergo hematopoietic differentiation in the
presence or absence of Tet. Cells were collected at time points
corresponding with EB, BC, and HC formation with HCs
scored to ensure that TP was driving myelopoiesis as pre-
viously reported [24]. Examination of the TP-candidate genes
in this model demonstrated significant altered expression
(P< 0.05 and <0.001) of a number of Hox genes at various
stages of development. Moderate to substantial (up to 10-
fold) changes in expression were shown between control TP-
inactive and TP-active differentiating cells (Fig. 6). Hoxa6was
the most predominant of the candidate genes in this model.
Transient upregulation of the majority of genes, including
Hoxa6, was observed at either the EB (9=15) or BC (13=15)
stage of development. Hoxa5 and Hoxa7 expression was in-
creased considerably (8–10-fold) with EB formation and
Hoxb1 (10-fold) with BC formation. Hoxa6, a7, a9, b3, b4, and
b9 were all upregulated in both the early differentiating cells
FIG. 4. Induced Tel-PDGFRb expression in murine ES cells
leads to altered gene expression and phenotype. (A) Re-
presentative Western blot analysis of protein extracts obtained
from one of the ES cell clones stably transfected with the tet-
racycline (Tet)-responsive Tel-PDGFRb receptor plasmid (TP).
ES-TP clones were grown either in the presence (þ) or absence
() of Tet for 24, 48, or 72h. Expression of Tel-PDGFRb was
confirmed using the anti-PDGFRb receptor antibody, and
activation of signaling pathways was confirmed by anti-
phosphotyrosine (pTyr) antibody; SHP2 expression was used
to confirm equal loading of protein. Gels representative of the
level of TP expression and tyrosine phosphorylation. (B) RT-
PCR analysis showing increased expression of Hoxb4 and
Cdx4 after induction of Tel-PDGFRb (þ) compared with
control () for 24, 48, and 72h. The low expression house-
keeping genes (TBP and GusB) were included as positive
controls. (C) Histogram plots showing reduced alkaline
phosphatase positivity in ES cells expressing Tel-PDGFRb (TP
Tet) compared with noninduced (TP þTet), nonexpressing
(E14 þTet), and treatment (E14 Tet) controls. Values are
means SE of 3 independent experiments.
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(72 h TP expression) as well as during mesodermal and he-
mangioblast formation after TP expression, identifying these
as potential candidates involved in TP-mediated alterations
in hematopoietic transcriptional regulation. Hoxa5 and a10
were initially downregulated after short-term TP expression
but became upregulated during mesodermal and he-
mangioblast commitment. All of the candidate genes apart
from Hoxb2 were downregulated in the TP expressing HCs,
most notably for Meis1 (*4-fold).
Delayed activation of TP results in altered
differentiation and gene expression
Delayed activation of TP was examined by Tet removal at
the BC or HC stage of differentiation. Late activation of TP in
HC cells resulted in increased myeloid colony formation at
the expense of erythroid and mixed colonies (Fig. 7A). These
phenotypic changes, reflected by changes in differentiation
marker gene expression, were dependent on conditional TP
activation and defined stage of development (Fig. 7B). Lower
Hoxb4 and EpoR expression in HC cells was more dependent
on development stage than TP status. In contrast, conditional
activation of TP resulted in a marked upregulation of GATA3
expression at the BC or HC stage of development. With the
exception of Hoxa10, which showed a moderate upregula-
tion, TP activation in BC cells had little effect on Hox-Tale
expression. Delayed TP activation in HC cells, however, re-
sulted in significant upregulation in Hoxa4, a5, a7, a13, b2, b3,
b4, and b5, with a 2-fold reduction in the expression of Hoxa6
(Fig. 7C). The candidate Hox-Tale signature increased, cu-
mulatively, by over 75% (10,578–18,782 copies) after activa-
tion of TP in HC cells.
FIG. 5. Comparative expression
analysis of a subset of Hox-Tale
candidate genes after Tel-PDGFRb
induction in a leukemic murine ES
cell model. Representative histo-
gram plot of copy number (per
50 ng of RNA) from 2 independent
experiments of activated Tel-
PDGFRb (TPþ) or control (TP)
murine ES cells for 24, 48, and 72 h.
Values obtained from triplicate ex-
periments normalized to 18S
rRNA SE are plotted. {P< 0.05
and *P< 0.001.
FIG. 6. RQ-PCR analysis of a
subset of Hox-Tale genes after sus-
tained Tel-PDGFRb induction in a
leukemic model of murine ES cell
differentiation. Representative his-
togram plot showing copy number
(per 50 ng of RNA) of the candi-
date genes at primary EB (18 EB):
BC and HC formation after induc-
tion of Tel-PDGFRb (TP) compared
with noninduced controls. Mean
values were obtained from tripli-
cate experiments normalized to 18S
rRNA SE. {P< 0.05 and *P< 0.001.
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Discussion
The ES=EB model used to track early events involved in
hematopoietic cell commitment and differentiation is now
well established [1,2,28]. Several researchers have elucidated
key signaling events that regulate self-renewal and lineage
commitment using this system (reviewed by Park et al. [29]).
Murine ES cells are maintained in the undifferentiated state
by the presence of LIF in the culture media. LIF signals
through its receptor gp130 to activate STAT3, which is suf-
ficient for retention of ES cells in their undifferentiated plu-
ripotent state [30]. Additional intracellular signal
transduction molecules, including other STATs [31], MAPK
[32], PI3K [23], TGF-Beta=Smad [33], and the members of the
Wnt family [5,34,35], have been shown to play a significant
role in hematopoietic development from ES cells. A modified
culture system that efficiently promotes the directed differ-
entiation of ES cells to the hematopoietic lineage [1] was
used. The sequential addition of specific growth factors is
critical for coordinated lineage restriction of the ES cells.
BMP-4 promotes efficient formation of mesoderm; bFGF and
activin A induce the differentiation of mesodermal precur-
FIG. 7. Delayed TP activation re-
sults in increased myeloid differen-
tiation and differential gene
expression of ES cells. (A) Percentage
of HC type formed by day 15 of
differentiation when TP was ex-
pressed only at the HC stage (days
8–15) (n¼ 3). (B) Representative RT-
PCR gels of differentiation markers
after delayed TP activation at the BC
or HC stage of development. (C)
Representative histogram of Hox-Tale
copy numbers (per 50 ng RNA) ob-
tained from RQ-PCR analysis after
delayed activation of TP at the BC or
HC stage. Mean values were ob-
tained from triplicate experiments
normalized to 18S rRNA SE.
{P< 0.05 and *P< 0.001.
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sors to hemangioblasts; and VEGF and SCF regulates
the production of fully committed hematopoietic progeni-
tors. The stepwise production of HCs allows for molecular
dissection of the key stages of hematopoietic develop-
ment [36].
BMP-4 signaling appears to play 2 distinct and sequential
roles during ES-derived hematopoiesis at least in part by
activation of the Cdx-Hox pathway [37]. FGF regulation of
the Cdx-Hox axis has been established in other develop-
mental models [38] and a Cdx-Hox code may actually control
the effectiveness of FGF signaling [39]. Similarly VEGF sig-
naling is associated with differential Hoxb expression [40].
Members of the TGFb superfamily, including Activin A,
have previously been identified as regulators of the Hox axis
[41] and more recently direct interaction between specific
Hox proteins and TGFb=BMP downstream regulators have
been identified [42,43]. Differential expression of Cdx4 and
Hoxb4 was initially confirmed in the ES model and quanti-
tative profiling of the Hox network extended these findings
to the complete Hox network. Cdx4 expression was initially
downregulated during formation of the EBs in the presence
of BMP-4 but became dramatically upregulated during pro-
duction of BCs and hematopoietic progenitors, perhaps in
part due to the biphasic activity of BMP-4.
Induction of differentiation in the normal ES model re-
sulted in a robust downregulation of the majority of Hox
genes, including Hoxb4, reflected by an increased CT value
and reduced copy number. Global downregulation of Hox
genes is a hallmark of differentiation and may reflect global
epigenetic regulation of the clusters [44,45]. The increased
expression of Hoxa13, c8, and c10 throughout the differenti-
ation process points to specific Hox regulation associated
with the early stages of hematopoiesis. The marked upre-
gulation of the Hoxd cluster, with the exception of Hoxd12,
also suggests privileged global regulation of this cluster
during ES differentiation as previously reported [46]. This
global activation may be controlled in part by an underlying
mechanism of nuclear reorganization that results in looping
out of the Hoxd cluster from its chromosomal territory [47].
Whether this nuclear reorganization is maintained in tissue-
specific developmental processes such as hematopoiesis
requires further study. The Hoxa cluster is generally well
expressed in hematopoietic tissue and its deregulation is
often associated with leukemia [9]. Comparative analysis of 2
independent ES cell lines undergoing hematopoietic differ-
entiation demonstrated reciprocal coordinated expression of
the Hoxa cluster. The more anterior 30 subset (Hoxa1-Hoxa7)
showed consistent reduced expression during all 3 key
stages of differentiation. Conversely, the more posterior 50
subset (Hoxa9-Hoxa13) showed differentiation associ-
ated downregulation followed by a moderate to substantial
increase in expression upon formation of the hematopoi-
etic progenitor cells. Both the degree and trend of expres-
sion appeared coordinated around cluster position, with
Hoxa6=7 acting as the fulcrum. The trend in expression
was similar for both cell lines with the E14tg2a cell line
showing greater degree of expression change throughout the
network.
Oncogenic activation of TP results in an MPN with accu-
mulation of myelomonocytic cells. In the leukemic model,
the transforming TP oncoprotein self-associates and activates
kinase-dependent signaling pathways [48]. Previous studies
demonstrate that TP inhibits ES self-renewal and promotes
myeloid differentiation [24,49]. This phenotype was vali-
dated by reduction in alkaline phosphatase expression and
upregulation of Hoxb4 and Cdx4. Increased Hoxb4 and Cdx4
expression levels are known to enhance the clonogenic po-
tential of EB-derived cells during hematopoietic differentia-
tion [49,50]. Recent evidence suggests that Cdx4 is
upregulated in 23% of AML patients, with preferential ex-
pression shown in primitive stem and progenitor cells. In
addition, Cdx4-transduced bone marrow demonstrated se-
rial re-plating ability of primitive myelomonocytic-like cells
[20]. Further, the impaired hematopoietic phenotype of Cdx
mutant mice can be rescued by multiple Hox genes [51].
Therefore, Cdx4 may play an important role in modulating
the Hox network to bias myelomonocytic differentiation in
the TP model.
Short-term TP activation in ES cells resulted in increased
expression of Hoxa13 and Hoxb2 (up to 6-fold). Hoxa13 is
recognized as playing a role in normal limb development,
but overexpression has been observed in models of leukemia
and in small cell lung carcinoma [52]. Hoxb2 is part of a
common Hox repertoire associated with self-renewal [53] and
expansion potential of another ES cell line (D3) and bone
marrow-derived mesenchymal stem cells [54]. Extended
analysis identified Hoxa6, b1, b2, b4, and Meis1 as displaying
measurable to substantial upregulation (up to 16-fold for
Meis1) after TP activation. Hoxb4 is well established as a
self-renewal factor for ES and LT-HSCs [16] and we have
previously shown Hoxa6 to affect hematopoietic cell prolif-
eration and self-renewal [55]. The striking and sustained
upregulation of Meis1 suggests that it plays a key role in the
oncogenic pathway initiated by TP activation. Meis1 is an
established Hox collaborator and its expression has been
shown to track with Hox genes during ES differentiation [56].
Meis1 cooperates with Cdx4 to accelerate AML development
in mice through upregulation of Hoxa6, a7, a9, b8, b4, and c6
[20] and has been associated with regulating other Hox genes
such as Hoxb1 and b2 [57].
Hematopoietic differentiation of TP expressing ES cells
resulted in upregulation of Hoxa6, a7, a9, b1, b2, b3, b4, and b9
between days 3 and 8 of differentiation when cells undergo
mesodermal and hemangioblast=HSC formation. Meis1 was
also upregulated in the BC when the first hemangioblasts
and HSC form. To test if the TP-induced transcriptional effects
were ES cell specific, conditional TP expression (-Tet) was
delayed until the BC (days 4–8) or HC (days 8–15) stage of
development. Quantitative PCR analysis of the Hox candi-
dates identified 9 genes (Hoxa4, a5, a7, a13, b2, b3, b4, b5, and
Meis1) that were upregulated after TP expression at the HC
stage rather than BC stage. To further examine the TP-induced
Hox candidates in a hematopoietic progenitor cell line, an
FDCP-Mix-TPþ model was used [57,58]. Constitutive expres-
sion of TP in the FDCP-Mix cell line (day 0) resulted in dif-
ferentiation with an associated upregulation of Hoxa6, a7, a9,
a10, b2, b3, b4, and Meis1 compared with EV controls. As
expected the Hox expression was reduced to barely detectable
levels after differentiation of the FDCP-Mix cells, validating
this model. Together, these findings demonstrate that onco-
gene-specific disruption of genetic networks may govern the
leukemic cell phenotype. Expression of a core subset of
Hox genes (a7, a9, b2, b3, and b4) is enhanced, along withMeis1
and Cdx4, in the presence of TP throughout hematopoietic
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differentiation and may represent part of the leukemia stem
cell signature along with Nanog, Oct4, c-kit, and Flk-1 [24].
The temporal and spatial expression of Hox genes is
tightly regulated at both the genetic and epigenetic level.
This study demonstrates for the first time transcriptional flux
through the Hox network during normal hematopoietic and
TP-induced leukemic differentiation of ES cells. Quantitative
complete Hox network profiling confirms and extends pre-
vious published reports and identifies a novel subset of
genes with potential roles in establishing early hematopoietic
commitment. Due to the high degree of redundancy built
into the network, loss-of-function studies involving individ-
ual Hox genes and clusters have provided limited informa-
tion on the importance of this family in hematopoiesis. This
study highlights that this is probably due to changes in
several Hox genes influencing hematopoietic regulation.
Overall, this study has identified how the Hox gene expres-
sion pattern alters during key stages of hematopoietic dif-
ferentiation and establishes Hox signatures that change in
response to an active tyrosine kinase involved in an MPN.
Upregulation of Cdx4, Meis1, Hoxa7, a9 b2, b3, and b4 are an
emerging theme in myeloid malignancies and warrant fur-
ther investigation as potential targets for future therapies or
intervention.
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